Q2 2023 Biosyent Inc Earnings Call Transcript
© -
Hello and welcome to the BioSyent Inc. Q2 and First Half 2023 Results Presentation. My name is René Goehrum and I'm the President and CEO of the company. I want to bring your attention to our disclaimer regarding forward-looking statements and we'll dive into the presentation looking first at our sales results in the quarter.
So this is for the period ending June 30, 2023, on a quarter basis and on a half basis. You can see our Canadian Pharmaceutical business performed well at 23% growth, reaching just over $7.7 million and on a 6-month basis for the first half, up 12%. The drivers of this performance could be characterized across the portfolio and we had a strong performance on FeraMAX at 25% up for the quarter, Tibella at 49%, Combogesic and RepaGyn showing a slightly less growth. And then looking at those brands on a 6-month basis, you can see FeraMAX up 13%, Tibella up 44%. Some decline in the Combogesic business that was notable from the first quarter. Obviously, we made up for some of that ground in the second
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |